Impact of Migraine

For your patients with 4-14 MHDs per month,

Emgality significantly reduced the impact of migraine on daily activities1

Patients completed the RF-R domain of the MSQ v2.1, a functional impact tool1,5

MSQ v2.1 is a self-administered tool developed to assess the impact of migraine on patients’ health-related quality of life.1,5

  • Areas measured included: relationships with family and friends, leisure time, productivity, concentration, energy, and tiredness
  • Scores are scaled from 0 to 100, with higher scores indicating less impact of migraine on daily activities
32.4 points image
  • In EVOLVE-1, Emgality demonstrated a mean improvement of 32.4 points from baseline (N=189) vs 24.7 points with placebo (N=377) over Months 4 to 6 (baseline: 51.4 points vs 52.9 points) (p<0.001)1
28.5 points image
  • In EVOLVE-2, Emgality demonstrated a mean improvement of 28.5 points from baseline (N=213) vs 19.7 points with placebo (N=396) over Months 4 to 6 (baseline: 52.5 points vs 51.4 points) (p<0.001)1

See Study Design for EVOLVE-1 and EVOLVE-2

SELECT IMPORTANT SAFETY INFORMATION
Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Get eligible patients started today with the Emgality savings card


References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018:75(9):1080-1088. 3. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0001. 5. Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52:409-421. 6. Data on File. Lilly USA, LLC. DOF-GZ-US-0002. 7. Data on File. Lilly USA, LLC. DOF-GZ-US-0053. 8. Data on File. Lilly USA, LLC. DOF-GZ-US-0054. 9. Data on File. Lilly USA, LLC. DOF-GZ-US-0024. 10. Data on File. Lilly USA, LLC. DOF-GZ-US-0010. 11. Data on File. Lilly USA, LLC. DOF-GZ-US-0012. 12. Data on File. Lilly USA, LLC. DOF-GZ-US-0025. 13. Data on File. Lilly USA, LLC. DOF-GZ-US-0015. 14. Data on File. Lilly USA, LLC. DOF-GZ-US-0016. 15. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337-1345.

Indication and Important Safety Information
Indication

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the pen and prefilled syringe.


GZ HCP ISI 27SEP2018